Namilumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Namilumab" in English language version.

refsWebsite

Global rank English rank

274^th place

309^th place

2clinicaltrials.gov

5,225^th place

4,062^nd place

195^th place

302^nd place

1acrabstracts.org

low place

low place

1takedaclinicaltrials.com

low place

low place

acrabstracts.org

Huizinga T, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E (October 2015). "Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA): Abstract Number: 969". Arthritis & Rheumatology. 67.

clinicaltrials.gov

Clinical trial number NCT02129777 for "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis" at ClinicalTrials.gov
Clinical trial number NCT02379091 for "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)" at ClinicalTrials.gov

springer.com

adisinsight.springer.com

"Namilumab". Adis Insight. Springer Nature Switzerland AG. Retrieved 2017-03-24.
"A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate". Adis Insight. Springer Nature Switzerland AG. Retrieved 2017-03-24.

takedaclinicaltrials.com

"Namilumab". Takeda clinical trials summary.

who.int

World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).